DCTH
Delcath Systems IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$382.90M
P/E Ratio
157.43
EPS
$0.07
Beta
0.54
52W High
$18.23
52W Low
$8.12
50-Day MA
$9.82
200-Day MA
$10.19
Dividend Yield
—
Profit Margin
3.17%
Forward P/E
25.77
PEG Ratio
1.60
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $85.23M |
| Gross Profit (TTM) | $73.43M |
| EBITDA | 898,000 |
| Operating Margin | -10.50% |
| Return on Equity | 3.00% |
| Return on Assets | 0.41% |
| Revenue/Share (TTM) | $2.38 |
| Book Value | $3.21 |
| Price-to-Book | 3.35 |
| Price-to-Sales (TTM) | 4.49 |
| EV/Revenue | 3.309 |
| EV/EBITDA | 279.49 |
| Quarterly Earnings Growth (YoY) | -66.70% |
| Quarterly Revenue Growth (YoY) | 37.30% |
| Shares Outstanding | $34.45M |
| Float | $28.78M |
| % Insiders | 8.14% |
| % Institutions | 50.59% |
Historical Volatility
HV 10-Day
52.12%
HV 20-Day
41.65%
HV 30-Day
37.98%
HV 60-Day
50.52%
HV Rank
11.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($21.33 target)
1
Strong Buy5
BuyMore HEALTHCARE Stocks
Data last updated: 5/5/2026